Genomic Health Inc. (GHDX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
29.95-0.41 (-1.35%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close30.36
Bid0.00 x
Ask0.00 x
Day's Range29.72 - 30.83
52wk Range20.54 - 35.79
1y Target EstN/A
Market Cap999.8M
P/E Ratio (ttm)-36.26
Avg Vol (3m)212,273
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire14 hours ago

    Genomic Health to Announce Third Quarter 2016 Financial Results and Host Conference Call on Tuesday, November 1, 2016

    REDWOOD CITY, Calif., Oct. 25, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, November 1 at 4:30 p.m. Eastern ...

  • StreetAuthority Network13 days ago

    This Innovative Healthcare Stock Belongs In My Portfolio -- What About Yours?

    Nestled within the beauty of Maine's Acadia National Park, on the picturesque Mount Desert Island, is a place known to many scientists and health care investors as the place where the term "

  • PR Newswire15 days ago

    Genomic Health Presents Robust Analytical Validation Study Results of Oncotype SEQ™ Liquid Biopsy Mutation Panel

    REDWOOD CITY, Calif., Oct. 11, 2016 /PRNewswire/ -- Genomic Health, Inc. (GHDX) today announced results from its successfully completed analytical validation study of Oncotype SEQ™ Liquid Select, which demonstrated that this liquid biopsy mutation panel is highly sensitive, specific and reproducible. To provide transparent and clinically meaningful performance standards, the analytical performance for Oncotype SEQ is reported on a per-sample basis rather than a per-DNA base measure. "The high specificity, sensitivity and reproducibility of Oncotype SEQ validated in this study ensures reliable and actionable liquid biopsy test results that physicians can routinely use in clinical practice to help drive precision medicine and enable patients to make more informed treatment decisions," said Phil Febbo, M.D., chief medical officer, Genomic Health.